Table 1.
Clinical baseline characteristics of patients enrolled in the included studies.
| Study | Year | Study design | Control group | Patients | RDN (n) | Age | Gender (male/female) | BMI (kg/m2) | Diabetes | Dyslipidemia |
|---|---|---|---|---|---|---|---|---|---|---|
| Almeida et al. | 2016 | Prospective | No | RH | 31 | 65 ± 7 | 15/16 | 31.8 ± 5.5 | 22 | 21 |
| Brandt et al. | 2012 | Prospective | Yes | RH | 46 | 63.1 ± 10.2 | 31/15 | 28.6 ± 3.4 | 21 | 32 |
| Dores et al. | 2014 | Prospective | No | RH | 34 (22a) | 62.7 ± 7.6 | 17/17 | 30.9 ± 5.3 | 22 | 23 |
| Feyz et al. | 2017 | Prospective | No | RH | 31 | 64 ± 10 | 15/16 | 29 ± 4 | 8 | 22 |
| Gao1 et al. | 2021 | Prospective | No | RH | 30 | 55.93 ± 10.94 | 22/8 | – | 14 | 16 |
| Gao2 et al. | 2021 | Prospective | No | RH | 30 | 62.73 ± 12.50 | 22/8 | – | 16 | 13 |
| Kiuchi et al. | 2016 | Prospective | No | RH with CKD | 45 | 53.9 ± 11.3 | 26/19 | 30.2 ± 4.3 | 15 | – |
| Luo et al. | 2022 | Prospective | Yes | RH | 13 | 55 ± 15 | 6/7 | 26.84 ± 3.49 | 7 | 10 |
| McLellan et al. | 2015 | Prospective | No | RH | 14 | 64 ± 9 | 10/4 | 31 ± 3 | 2 | 10 |
| Palionis et al. | 2016 | Prospective | No | RH | 15 | 54 ± 7.2 | 8/7 | 34.46 ± 3.46 | 4 | 11 |
| Ripp et al. | 2015 | Prospective | No | RH | 60 | 54.6 ± 9.5 | 33/27 | 32.9 ± 6.2 | – | – |
| Schirmer et al. | 2014 | Prospective | No | RH | 66 | 63.5 ± 1.2 | 36/30 | 29.4 ± 0.6 | 23 | 42 |
| Tsioufis et al. | 2015 | Prospective | Yes | RH | 18 | 56 ± 10 | 12/6 | 33.6 ± 5.4 | 6 | 10 |
| Study | Coronary heart disease | Atrial fibrillation | Stroke | Antihypertensive drugs | Follow‐up (month) | Interesting endpoints |
|---|---|---|---|---|---|---|
| Almeida et al. | 10 | 1 | 2 | 5.8 ± 1.1 | 12 | LVMI, LVIDd, PWTd, IVSTd, LVEF, E/A |
| Brandt et al. | 20 | 7 | 8 | 4.7 ± 0.5 | 1, 6 | LVMI, LVIDd, PWTd, IVSTd, LVEF, E/A |
| Dores et al. | 7 | – | 3 | 5.8 ± 1.0 | 6 | LVMI, LVEF, E/A |
| Feyz et al. | 16 | 2 | – | 4 ± 1 | 6 | LVMI, LVIDd, PWTd, IVSTd, LVEF, E/A |
| Gao1 et al. | 6 | 3 | 6 | 3.13 ± 1.04 | 12 | LVIDd, PWTd, IVSTd, LVEF |
| Gao2 et al. | 10 | 1 | 2 | 3.73 ± 1.20 | 12 | LVIDd, PWTd, IVSTd, LVEF |
| Kiuchi et al. | 6 | 2 | 6 | 4.7 ± 1.2 | 6 | LVMI, LVIDd, PWTd, IVSTd, LVEF |
| Luo et al. | – | – | – | 5.23 ± 1.01 | 12 | LVIDd, PWTd, IVSTd, LVEF |
| McLellan et al. | 2 | 2 | 3 | 4.9 ± 1.8 | 6 | LVMI, LVIDd, PWTd, IVSTd, LVEF |
| Palionis et al. | 4 | – | – | 6.3 ± 1.1 | 6 | LVMI, LVIDd, PWTd, IVSTd, E/A |
| Ripp et al. | – | – | – | – | 6 | LVMI, LVIDd, PWTd, IVSTd, LVEF, E/A |
| Schirmer et al. | 14 | – | – | 4.3 ± 0.1 | 6 | E/A |
| Tsioufis et al. | – | – | – | 4.5 ± 0.6 | 6 | LVMI, LVIDd, PWTd, IVSTd, LVEF, E/A |
Note: Continuous variables are expressed as mean ± SD or median (interquartile range).
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; IVSTd, end‐diastolic interventricular septum thickness; LVEF, left ventricular ejection fraction; LVIDd, end‐diastolic left ventricular internal dimension; LVMI, left ventricular mass index; PWTd, left ventricular end‐diastolic posterior wall thickness; RH, resistant hypertension.
a
Number of patients who completed follow‐up.